Skip to content

    Granules India Limited

    GRANULES
    Healthcare·23 Jan 2026
    Management Summary

    Granules India delivered a strong Q3 FY26, reporting a 22% YoY revenue growth to INR1,388 crores and a 34% YoY EBITDA increase to INR308 crores, despite a temporary INR248 million loss in its Peptide CDMO business. The company made substantial regulatory progress across its facilities, including a post-warning letter meeting for Gagillapur and multiple GMP certifications/approvals. Granules is strategically focusing on higher complexity generics and anticipates new product launches from its Genome Valley facility and in controlled substances, aiming for continued growth and profitability.

    Highlights

    5

    • Revenue grew 22% year-on-year to INR1,388 crores, with sequential growth of 7% from Q2 FY26.

    • EBITDA increased 34% year-on-year to INR308 crores, and EBITDA margin improved by 196 basis points YoY to 22.2%.

    • Net debt reduced to INR10,151 million from INR10,241 million in Q2 FY26, and ROCE improved to 16.8% from 16.2% QoQ.

    • Significant regulatory progress with ANVISA Brazil GMP certification for Gagillapur, PAS approval and EIR for GLS, and clean GMP inspections for GPI USA and GCH.

    • Preferential issue completed, strengthening the balance sheet and enhancing financial flexibility for capacity expansion.

    Concerns

    3

    • Temporary EBITDA loss of INR248 million from Ascelis Peptides CDMO business due to planned maintenance and higher execution activities.

    • Gross margin decreased by 183 basis points sequentially, although it improved 216 basis points year-on-year to 63.9%.

    • Observed some amount of price erosion in paracetamol in certain markets despite increased demand.

    Key financials

    Single quarter

    07 metrics
    1. 01Revenue13,880 Mn+22%YoY
    2. 02EBITDA3,080 Mn+34%YoY
    3. 03EBITDA Margin22.2%
    4. 04Gross Margin63.9%
    5. 05R&D Expenses689 Mn

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹1,298 million

    Debt

    Net ₹10,151 million

    Liquidity

    Liquidity disclosed

    Preferential issue enhanced financial flexibility.

    Guidance & targets

    5
    CategoryTargetPriority
    Profitability
    Peptide CDMO EBITDA
    positive
    		Medium
    Revenue
    US Revenue Growth
    $40-50 million
    		Medium
    Capacity
    Gagillapur Capacity
    increasing capacities
    		High
    Product Launches
    Genome Valley Product Launches
    at least 1, if not 2 products
    		High
    Product Launches
    Controlled Substances Launches
    3 to 4 launches
    		High

    What to watch in Q4 FY26

    5

    Gagillapur FDA Warning Letter Resolution

    next quarter
    CurrentPost-warning letter meeting held, documentation submission underway
    TargetFormal feedback received, progress towards resolution

    Why it matters

    Resolution of the FDA warning letter is crucial for full operational flexibility and market confidence.

    We held a post-warning letter meeting with the FDA in early January. We will be submitting the requested documentation shortly. Importantly, to date, the agency has not raised any concerns regarding the adequacy or pace of our corrective action. We expect a formal feedback after our submission and remain confident about the pathway to resolution.

    Risks & concerns

    4
    RiskSeverity

    Gagillapur FDA Warning Letter

    Ongoing remediation plan, post-warning letter meeting held, documentation being submitted, but no timeline for final resolution. — Management acknowledged

    medium

    Peptide CDMO Business Losses

    Temporary EBITDA loss of INR248 million in Q3 FY26 due to planned maintenance and higher execution activities, expected to improve in Q4 and turn positive in FY27. — Management acknowledged

    medium

    Paracetamol Price Erosion

    Some amount of price erosion observed in paracetamol in certain markets despite increased demand. — Management acknowledged

    low

    Amphetamine (generic Adzenys) Litigation Delay

    Tentative FDA approval for generic Adzenys, but launch is dependent on resolution of ongoing litigation, expected to take 'a year'. — Management acknowledged

    medium

    Q&A highlights

    8

    “We cannot put a timeline to that, but we will be submitting the response quite early in the very near future. But we'll have to see how the agency and then what timelines are going to come out. But again, like I mentioned, we have also been de-risking. Some of the filings have been happening in our U.S. facility and also at our GLS facility.”

    Analyst sought a timeline for FDA warning letter resolution, a key overhang. Management confirmed progress and de-risking but could not provide a specific timeline, indicating continued uncertainty.

    asked by Krisha Kansara

    2 min read6 chapters

    Detailed Narrative

    01

    Robust Q3 FY26 Performance Driven by Formulations

    Granules India reported a strong Q3 FY26, with revenues reaching INR1,388 crores, marking a 22% increase year-on-year and 7% sequential growth. EBITDA grew by 34% year-on-year to INR308 crores, leading to an EBITDA margin of 22.2%, an improvement of 196 basis points YoY. This growth was broad-based, with significant contributions from the formulation business in North America and Europe, and improved operating leverage.

    02

    Significant Regulatory Milestones Achieved

    The company made substantial progress on regulatory fronts across its facilities. A post-warning letter meeting for the Gagillapur facility was held with the FDA in early January, with documentation submission underway and no concerns raised by the agency. The GLS facility at Genome Valley received a PAS approval and EIR, and its US FDA inspection resulted in only five observations with no data integrity issues. Additionally, the GPI facility in the USA and GCH packaging site also received clean GMP inspections, reinforcing the company's commitment to regulatory excellence.

    03

    Peptide CDMO Business Poised for Turnaround

    The Peptide CDMO business, Ascelis Peptides, experienced a temporary EBITDA loss of INR248 million in Q3 FY26, primarily due to planned maintenance activities and higher execution costs for key customer projects. However, management anticipates a 'meaningful improvement' in Q4 FY26, with the business targeted to achieve positive EBITDA from the next financial year (FY27). The India R&D setup at IIT Hyderabad is actively contributing to customer projects, focusing on advanced peptide chemistries.

    04

    Strategic Focus on Higher Complexity Generics and Market Expansion

    Granules is strategically shifting towards higher complexity generics, evidenced by R&D filings including 1 EU dossier, 8 new product registrations in ROW markets, and 4 DMFs. The company secured a tentative US FDA approval for generic Adzenys and multiple approvals in Europe and ROW markets. Management highlighted strengthening market presence across key geographies and scaling operations at GLS as regulatory milestones translate into commercial execution, with plans to file more products inclined towards complex generics.

    05

    Financial Health and Future Growth Initiatives

    The company's financial health remained robust, with net debt reducing to INR10,151 million and the cash-to-cash cycle improving to 202 days. ROCE increased to 16.8% in Q3 FY26. A preferential issue was successfully completed, providing financial flexibility for capacity expansion and value-accretive opportunities. Granules expects to launch at least 1-2 new products from its Genome Valley facility within the next two quarters and 3-4 controlled substances within 1-1.5 years, which are anticipated to be significant growth drivers.

    06

    Digitalization and Sustainability Efforts

    Granules continues to advance digitalization of manual operations across its network, with implementation expected at Gagillapur by mid-calendar year. These system enhancements, involving both capex and opex, aim to strengthen reliability and resilience. On the ESG front, the company's CDP climate change rating improved to 'A' from 'B', and its S&P CSA score increased to 62, placing it among the top 10% of global peers. The Gagillapur facility also achieved zero waste to landfill with over 99% waste diversion.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.